Addition of targeted agents to chemotherapy for persistent or recurrent ovarian cancer: a meta-analysis of randomized controlled trials
The majority of epithelial ovarian cancer patients who achieve a full remission following first-line chemotherapy would finally develop recurrent disease. However, the optimal management of recurrent ovarian cancer (ROC) remains undefined. The preset meta-analysis aims to evaluate the role of novel targeted agents (TAs) in the treatment of ROC in terms of response, overall survival and toxicities.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Xiao Li, Yuchan Mao, Qiwen Wu, Yuanyuan Liu, Qianqian Wu, Binghuan Wen Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Epithelial Cancer | Hematology | Ovarian Cancer | Ovaries | Toxicology